Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Solid find. Just a quick question- how do they split profits with PAR pharma if this gets to market?

This announcement just mentions a royalty if it gets to market.

Under the terms of the agreement, Optimer will fund all expenses associated with the clinical trials of PAR-101. Par will be responsible for clinical development, and, if successful, Par will submit the New Drug Application for the product. All legal and regulatory responsibilities also reside with Par. If ultimately cleared for marketing, Par will manufacture and market PAR-101. Par has exclusive rights to market, sell and distribute the product in the U.S. and Canada. Par will pay Optimer a royalty on sales of the product. Par has an option to extend the joint development and collaboration agreement to include up to three additional drug candidates from Optimer's pipeline.

Where do I look for more details? Into the SEC filings?

BTW, this is making me like one of my other potential picks for the contest even better - since it recently got its european marketing rights back from a partner. Hmmm...thinking...

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.